United Therapeutics’ Treatment Options

Committed to making a difference

United Therapeutics is committed to helping patients with PAH by offering treatments in a variety of delivery formulations to meet your needs now and over the course of your disease. That's why we have spent 2 decades studying a prostacyclin analogue called treprostinil. We have developed a family of treprostinil formulations so that more patients may benefit from prostacyclin class therapy.

OUR TREPROSTINIL FAMILY
Orenitram
Oral treprostinil

Treprostinil oral tablets

Tyvaso
Treprostinil inhalation

Inhaled treprostinil delivered directly to the lungs

Remodulin
Treprostinil injection

Infused treprostinil delivered via a subcutaneous or intravenous pump

Please see Indication and Important Safety Information for Orenitram, Tyvaso, and Remodulin below.

Speech bubble
Speech bubble

Every patient is different, so talk to your doctor about which form of treprostinil may be right for you.

For more information on improving the treatment conversation with your doctor, use our Doctor Discussion Tool.

ORENITRAM (TREPROSTINIL) EXTENDED-RELEASE TABLETS

IMPORTANT SAFETY INFORMATION

Do not take Orenitram if you have severe liver problems.

Before you take Orenitram, tell your healthcare provider if you:

  • Have liver problems, diverticulosis, or any other medical conditions

  • Are pregnant, breastfeeding, and/or plan to become pregnant or breastfeed. It is not known if Orenitram will harm your unborn baby or if Orenitram passes into your breast milk. You and your healthcare provider should decide if you will take Orenitram or breastfeed. You should not do both

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Orenitram and other medicines may affect each other causing side effects. Do not start or stop any new medicine until you check with your healthcare provider. Especially tell your healthcare provider if you take another medicine that contains the same ingredient, treprostinil. Know the medicines you take. Keep a list of them and the dose you take to show to your healthcare provider and pharmacist when you get a new medicine.

Do not change your dose or suddenly stop taking Orenitram without first talking to your healthcare provider. Stopping Orenitram suddenly may cause worsening of your PAH symptoms. If you miss two or more doses of Orenitram, call your healthcare provider. If you take too much Orenitram, call your healthcare provider or go to the nearest hospital emergency room right away.

If Orenitram tablets are not taken whole, they may release too much medicine at one time. This can lead to side effects. Do not split, chew, crush, or break your Orenitram tablets. Do not take Orenitram tablets that are damaged or broken. Take Orenitram with food.

Orenitram can cause serious side effects, including an increased risk of bleeding. This risk could be increased if you are taking blood thinners such as warfarin.
The most common side effects of Orenitram include headache, diarrhea, nausea and flushing. These are not all of the possible side effects of Orenitram. Tell your doctor about any side effects that bother you, get worse over time, or do not go away.

INDICATION

Orenitram is a prescription medicine used to treat pulmonary arterial hypertension (PAH) which is high blood pressure in the arteries of your lungs. Orenitram may improve your ability to exercise. It is not known if Orenitram is safe and effective in children under 18 years of age.

Please see Full Prescribing Information and Patient Information for Orenitram.

OREISIdtcJAN16


TYVASO (TREPROSTINIL) INHALATION SOLUTION

IMPORTANT SAFETY INFORMATION

What is Tyvaso?

Tyvaso (treprostinil) is a prescription medicine used in adults to treat pulmonary arterial hypertension (PAH; WHO Group I), which is high blood pressure in the arteries of your lungs. Tyvaso can improve the ability to exercise. Your ability to exercise decreases 4 hours after taking Tyvaso. It is not known if Tyvaso is safe and effective in children under 18 years of age.

IMPORTANT SAFETY INFORMATION

Before you take Tyvaso, tell your healthcare provider about all of your medical conditions, including if you:

  • Have lung disease, such as asthma or chronic obstructive pulmonary disease (COPD)

  • Have a lung infection

  • Have liver or kidney problems

  • Have low blood pressure

  • Have bleeding problems

  • Are pregnant or plan to become pregnant. It is not known if Tyvaso will harm your unborn baby.

  • Are breast-feeding or plan to breast-feed. It is not known if Tyvaso passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with Tyvaso.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tyvaso and other medicines may affect each other.

Especially tell your healthcare provider if you take:

  • Medicines used to treat high blood pressure or heart disease

  • Medicines that decrease blood clotting (anticoagulants)

  • Water pills (diuretics)

  • Gemfibrozil (Lopid) or rifampin (Rimactane, Rifadin, Rifamate, Rifater)

What are the possible side effects of Tyvaso?

Tyvaso can cause serious side effects, including:

  • Low blood pressure (symptomatic hypotension). If you have low blood pressure, Tyvaso may lower your blood pressure more.

  • Bleeding problems. Tyvaso may increase the risk of bleeding in people who take blood thinners (anticoagulants).

The most common side effects of Tyvaso are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, and diarrhea. These are not all the possible side effects of Tyvaso. Call your doctor for medical advice about side effects.

Please see the Full Prescribing Information, Patient Package Insert, and the Tyvaso Inhalation System Instructions for Use manual.

You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.

TYVISIdtcOCT17


REMODULIN (TREPROSTINIL) INJECTION

Important Safety Information

  • Continuous intravenous (IV) infusions of Remodulin are delivered using a tube placed in a central vein within the chest. This type of delivery is associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery

  • You should not stop or greatly reduce your Remodulin dose without consulting your doctor, as this may cause your PAH symptoms to worsen

  • Other medical conditions and medicines may affect your use of Remodulin by increasing the risk of side effects or decreasing the drug's effectiveness. It is important to tell your doctor about your medical conditions and any medicines you may be taking

  • If you have liver or kidney problems, your ability to tolerate Remodulin may be affected

  • If you are taking gemfibrozil (for high cholesterol), rifampin (for infection), or other drugs that affect liver enzymes, your doctor may need to adjust your Remodulin dosage

  • Remodulin acts by lowering your blood pressure. In some cases your blood pressure may become too low and cause other side effects. If you also take other drugs that lower your blood pressure, the risk is increased. You should discuss all of your symptoms with your doctor, including those associated with low blood pressure

  • Because Remodulin can reduce the blood's ability to clot, it may increase your risk of bleeding, especially if you are taking anticoagulants (blood thinners)

  • If you are pregnant, breast-feeding, or planning to become pregnant, talk with your doctor about whether you should take Remodulin

  • Side Effects: In clinical studies of SC infusion of Remodulin, most people experienced infusion site pain and infusion site reaction (redness and swelling). These symptoms were often severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin has been associated with the risk of blood stream infections, arm swelling, tingling sensations, bruising, and pain. Other common side effects seen with either SC or IV Remodulin were headache, diarrhea, jaw pain, nausea, vasodilatation (widening of the blood vessels), and edema (swelling)

Indication for Remodulin

Remodulin is a prescription medication used in adults with pulmonary arterial hypertension (PAH; WHO Group 1), to diminish symptoms associated with exercise. PAH is high blood pressure in the arteries of your lungs. Remodulin was studied mainly in patients with NYHA Functional Class II-IV symptoms. Remodulin is delivered (infused) continuously using a pump connected to a small tube that is either placed under the skin (subcutaneously [SC]) or inserted into a vein in the upper chest (intravenously [IV]). Because there are risks associated with continuous IV infusion, such as serious blood stream infections, IV infusion should be reserved for people who cannot tolerate SC infusion or for those in whom the risks are considered acceptable.

In people with PAH who need to switch from Flolan® (epoprostenol sodium), Remodulin is approved to slow the worsening of symptoms. The risks and benefits of each drug should be carefully considered before switching.

Please see the Full Prescribing Information for Remodulin.


Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.